Show simple item record

dc.contributor.authorRichards, TM
dc.contributor.authorBhide, SA
dc.contributor.authorMiah, AB
dc.contributor.authorDel Rosario, L
dc.contributor.authorBodla, S
dc.contributor.authorThway, K
dc.contributor.authorGujral, DM
dc.contributor.authorRooney, KP
dc.contributor.authorSchick, U
dc.contributor.authorMcGovern, T
dc.contributor.authorGrove, L
dc.contributor.authorNewbold, KL
dc.contributor.authorHarrington, KJ
dc.contributor.authorNutting, CM
dc.date.accessioned2016-08-26T15:20:18Z
dc.date.issued2016-09
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2016, 28 (9), pp. e77 - e84
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/78
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2016.04.035
dc.description.abstractAims To determine the clinical outcomes of an intensity-modulated radiotherapy technique for total mucosal irradiation (TM-IMRT) in patients with head and neck carcinoma of unknown primary (HNCUP).Materials and methods A single-centre prospective phase II trial design was used in two sequential studies to evaluate TM-IMRT for HNCUP. Patients were investigated for primary tumour site using examination under anaesthetic and biopsies, computed tomography ± magnetic resonance imaging (MRI) or 18-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT). Patients received IMRT to the potential primary tumour sites and elective cervical nodes. Concomitant chemotherapy was used in patients who received primary radiotherapy or those with nodal extracapsular extension.Results Thirty-six patients with HNCUP were recruited; 72% male. Twenty-five patients (69.4%) had p16-positive disease. Two year mucosal and local nodal control rates were 97.1% (95% confidence interval 91.4-100) and 89.8% (78.4-100), respectively. One mucosal primary was detected 7.3 months after TM-IMRT and three patients died from recurrent/metastatic squamous cell carcinoma of the head and neck. Twelve patients (33%) developed grade 3 (Late Effects in Normal Tissue-Subjective, Objective, Management and Analytical; LENT-SOMA) dysphagia with a 1 year enteric tube feeding rate of 2.7%. The high-grade subjective xerostomia rate (LENT-SOMA) at 24 months after IMRT was 15%.Conclusions At a median follow-up of 36.1 months, the use of TM-IMRT was associated with good local control. Toxicity was comparable with previously reported TM-IMRT regimens encompassing similar mucosal volumes.
dc.formatPrint-Electronic
dc.format.extente77 - e84
dc.languageeng
dc.language.isoeng
dc.subjectMucous Membrane
dc.subjectHumans
dc.subjectCarcinoma, Squamous Cell
dc.subjectHead and Neck Neoplasms
dc.subjectNeoplasms, Unknown Primary
dc.subjectXerostomia
dc.subjectTomography, X-Ray Computed
dc.subjectRadiotherapy Dosage
dc.subjectProspective Studies
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectRadiotherapy, Intensity-Modulated
dc.subjectSquamous Cell Carcinoma of Head and Neck
dc.titleTotal Mucosal Irradiation with Intensity-modulated Radiotherapy in Patients with Head and Neck Carcinoma of Unknown Primary: A Pooled Analysis of Two Prospective Studies.
dc.typeJournal Article
dcterms.dateAccepted2016-03-03
rioxxterms.versionofrecord10.1016/j.clon.2016.04.035
rioxxterms.licenseref.startdate2016-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue9
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume28
pubs.embargo.termsNo embargo
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorMiah, Aishaen
dc.contributor.icrauthorHarrington, Kevinen
dc.contributor.icrauthorThway, Khinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record